These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 19896073)

  • 1. Proteasome inhibition and allogeneic hematopoietic stem cell transplantation: a review.
    Koreth J; Alyea EP; Murphy WJ; Welniak LA
    Biol Blood Marrow Transplant; 2009 Dec; 15(12):1502-12. PubMed ID: 19896073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Ex Vivo Treatment of Donor T Cells with Cosalane, an HIV Therapeutic and Small-Molecule Antagonist of CC-Chemokine Receptor 7, Separates Acute Graft-versus-Host Disease from Graft-versus-Leukemia Responses in Murine Hematopoietic Stem Cell Transplantation Models.
    Fowler KA; Li K; Whitehurst CB; Bruce DW; Moorman NJ; Aubé J; Coghill JM
    Biol Blood Marrow Transplant; 2019 Jun; 25(6):1062-1074. PubMed ID: 30668984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic stem cell transplantation for multiple myeloma.
    Bellucci R; Ritz J
    Rev Clin Exp Hematol; 2002 Sep; 6(3):205-24. PubMed ID: 12616696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic hematopoietic stem cell transplantation (HSCT) after reduced intensity conditioning.
    Servais S; Baron F; Beguin Y
    Transfus Apher Sci; 2011 Apr; 44(2):205-10. PubMed ID: 21345734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical outcome of allogeneic hematopoietic stem cell transplantation with FLAG sequential busulfan/cyclophosphamide conditioning regimen for refractory/relapsed acute myeloid leukemia].
    Liu W; Li Y; Qiu ZX; Yin Y; Sun YH; Xu WL; Wang Q; Liang ZY; Dong YJ; Wang LH; Cen QN; Wang MJ; Wang WS; Ou JP; Ren HY
    Zhonghua Nei Ke Za Zhi; 2018 Aug; 57(8):576-581. PubMed ID: 30060329
    [No Abstract]   [Full Text] [Related]  

  • 7. Impact of donor and recipient characteristics on graft-versus-host disease and survival in HLA-matched sibling hematopoietic stem cell transplantation.
    Zhang H
    Transfus Apher Sci; 2020 Jun; 59(3):102743. PubMed ID: 32139282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Chen YB; Shah NN; Renteria AS; Cutler C; Jansson J; Akbari M; Chen C; Quadri S; Parfionovas A; Devine SM
    Blood Adv; 2019 Dec; 3(23):4136-4146. PubMed ID: 31821456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating CD14(+) HLA-DR(-/low) myeloid-derived suppressor cells in leukemia patients with allogeneic hematopoietic stem cell transplantation: novel clinical potential strategies for the prevention and cellular therapy of graft-versus-host disease.
    Yin J; Wang C; Huang M; Mao X; Zhou J; Zhang Y
    Cancer Med; 2016 Jul; 5(7):1654-69. PubMed ID: 27109254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of anti-CD4 antibody treatment and donor lymphocyte infusion ameliorates graft-versus-host disease while preserving graft-versus-tumor effects in murine allogeneic hematopoietic stem cell transplantation.
    Ueha S; Yokochi S; Ishiwata Y; Kosugi-Kanaya M; Shono Y; Shibayama S; Ito S; Matsushima K
    Cancer Sci; 2017 Oct; 108(10):1967-1973. PubMed ID: 28787768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of "minitransplantation": nonmyeloablative allogeneic hematopoietic stem cell transplantation.
    Georges GE; Storb R
    Int J Hematol; 2003 Jan; 77(1):3-14. PubMed ID: 12568294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of reduced intensity conditioning in allogeneic hematopoietic cell transplantation for patients with multiple myeloma.
    Nishihori T; Kharfan-Dabaja MA; Ochoa-Bayona JL; Bazarbachi A; Pasquini M; Alsina M
    Hematol Oncol Stem Cell Ther; 2011; 4(1):1-9. PubMed ID: 21460601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Presalvage International Staging System Stage and Other Important Outcome Associations in CD34
    Bryant AR; Hilden P; Giralt S; Chung DJ; Maloy M; Landau H; Landgren O; Scordo M; Shah G; Smith EL; O'Reilly RJ; Perales MA; Koehne G
    Biol Blood Marrow Transplant; 2020 Jan; 26(1):58-65. PubMed ID: 31493537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High mortality in hematopoietic stem cell transplant-associated thrombotic microangiopathy with and without concomitant acute graft-versus-host disease.
    Kraft S; Bollinger N; Bodenmann B; Heim D; Bucher C; Lengerke C; Kleber M; Tsakiris DA; Passweg J; Tzankov A; Medinger M
    Bone Marrow Transplant; 2019 Apr; 54(4):540-548. PubMed ID: 30108323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasome inhibition in transplantation-focusing on the experience with bortezomib.
    Liang Y; Liu H
    Curr Pharm Des; 2013; 19(18):3299-304. PubMed ID: 23151133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-myeloablative transplants for malignant disease.
    Storb RF; Champlin R; Riddell SR; Murata M; Bryant S; Warren EH
    Hematology Am Soc Hematol Educ Program; 2001; ():375-91. PubMed ID: 11722994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The graft-versus-myeloma effect: chronic graft-versus-host disease but not acute graft-versus-host disease prolongs survival in patients with multiple myeloma receiving allogeneic transplantation.
    Donato ML; Siegel DS; Vesole DH; McKiernan P; Nyirenda T; Pecora AL; Baker M; Goldberg SL; Mato A; Goy A; Rowley SD
    Biol Blood Marrow Transplant; 2014 Aug; 20(8):1211-6. PubMed ID: 24792872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-1β and TLR4 signaling are involved in the aggravated murine acute graft-versus-host disease caused by delayed bortezomib administration.
    Liang Y; Ma S; Zhang Y; Wang Y; Cheng Q; Wu Y; Jin Y; Zheng D; Wu D; Liu H
    J Immunol; 2014 Feb; 192(3):1277-85. PubMed ID: 24363427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
    Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of graft-versus-host disease with rituximab-containing conditioning regimens in allogeneic hematopoietic stem cell transplant.
    Marini BL; Markstrom D; Frame D
    J Oncol Pharm Pract; 2017 Jun; 23(4):255-263. PubMed ID: 26970572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.